Weekly Recap: Everolimus suspension FDA OK and Oppenheimer $85 target
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) won final FDA approval for its Everolimus oral suspension ANDA (2, 3, 5 mg), targeting a branded U.S. market of about $123 million annually, and Oppenheimer set an $85 per-share price target on the stock.Previous Week RecapThis is an AI-generated summary and…